Recent news on

Increasing Use of Avastin, Erbitux, and Vectibix for Colorectal ...  -  May 21, 2007
PR Newswire (press release),...treatment of colorectal cancer will help to counter the loss of sales caused by the generics erosion of Sanofi-Aventis's Eloxatin and Yakult's Elplat.

Substantial Growth Forecasted for China's Colorectal Cancer Drug ...  -  May 16, 2007
PR Newswire (press release),Sanofi-Aventis's Eloxatin and Jiangsu LYC Hengrui's Ai Heng Will Continue to Dominate, According to a New Report by Decision Resources WALTHAM, Mass.,

Substantial Growth Forecasted for China's Colorectal Cancer Drug ...  -  May 16, 2007
PR Newswire (press release),The report also finds that Sanofi-Aventis's Eloxatin and Jiangsu LYG Hengrui's Ai Heng will continue to dominate the market, but that sales of Roche's

Sanofi Profit Declines 2.6% as Gain Not Repeated (Update1)  -  May 2, 2007
BloombergSales rose 2 percent as doctors prescribed rival copies of the Eloxatin cancer drug and the company failed to switch enough patients to a newer version of

Sanofi-Aventis Boosts Outlook  -  May 3, 2007
TheStreet.comAt the same time, its colorectal cancer drug Eloxatin is facing generic competition in Europe. In addition, the company is still waiting to hear from the

sanofi-aventis: Full-year Guidance Raised on Good 2007 First ...  -  May 3, 2007
PR Newswire (press release),In Europe, Eloxatin(R), which is facing competition from generics in some countries (in particular Germany and the United Kingdom), reported a 24.3% decline

Erbitux® Improves Outcomes in Advanced Colorectal Cancer  -  May 3, 2007
Cancer Consultants (press release),...[1] The study enrolled more 1298 patients with metastatic colorectal cancer that was resistant to Eloxatin® (oxaliplatin). Half the patients were treated

Sanofi raises profit forecast despite Ambien generic threat  -  May 3, 2007
Pharma Times (subscription),Eloxatin (oxaliplatin) slipped just 3.2% to 393 million euros and Amaryl (glimepiride) for diabetes was down 19% to 94 million euros.

EGFR-Targeted Therapies for Colorectal Cancer Linked to Lower ...  -  May 1, 2007
MedPage Today,...and folinic acid and/or oxaliplatin (Eloxatin). Matuxumab was studied in combination with irinotecan and panitumumab was studied as monotherapy.

Oral Glutamine Helps Prevent Side Effects Caused by Eloxatin®  -  Apr 19, 2007
Cancer Consultants (press release),Eloxatin is a commonly used chemotherapy agent in the treatment of colorectal cancer. Unfortunately, it is associated with a side effect called

Study Reviews Chemotherapy for Advanced Biliary Tract Cancer  -  Apr 4, 2007
Cancer Consultants (press release),Platinum chemotherapy drugs include Platinol® (cisplatin), Eloxatin® (oxaliplatin), and Paraplatin® (carboplatin). Because many of the reviewed studies had

Sanofi-Aventis: pipeline strengthening cancer vaccine deal  -  Mar 30, 2007
Pharmaceutical Business ReviewThe addition of TroVax would help to mitigate the reliance placed on its two main oncology products, the cytotoxic colorectal cancer treatment Eloxatin and

sNDA Submitted for Xelox  -  Mar 30, 2007
Cancer Consultants (press release),...of Xelox (Xeloda® (capecitabine) plus Eloxatin® (oxaliplatin)) with or without Avastin® (bevacizumab) for the treatment of metastatic colorectal cancer.

White House Press Secretary to Battle Second Round of Colon Cancer  -  Mar 28, 2007
MedIndia,The Food and Drug Administration has approved five new colorectal cancer drugs since 1996: Camptosar, Eloxatin, Erbitux, Avastin and Vectibix.

AACR: Cetuximab Shows Survival Edge as Third-Line Colorectal ...  -  Apr 17, 2007
MedPage Today,Among patients who failed 5-FU or capecitabine therapy as well as irinotecan and oxaliplatin (Eloxatin), cetuximab on top of best supportive care was

Onconova Therapeutics Announces Presentation of Clinical and Non ...  -  Apr 16, 2007
PharmaLive.com (press release),Na in combination with Eloxatin(R) (Sanofi-Aventis) is demonstrated in a poster presentation entitled, "ON 01910.Na enhances the in vivo cancercidal effects

Weekly Taxol®, Eloxatin®, Leucovorin and 5-FU Promising for ...  -  Mar 23, 2007
Cancer Consultants (press release),A second report at the same meeting suggested that Avastin® (bevacizumab) could be added to a regimen of Gemzar and Eloxatin without increasing toxicity and

Radioactive Microspheres plus Chemotherapy Provide Great ...  -  Mar 21, 2007
Cancer Consultants (press release),In addition to the radioactive microspheres, the patients were also treated with FOLFOX4 (5-fluorouracil, Eloxatin®, leucovorin).

[WTë…¼í?‰]Japan's cancer refugees  -  Mar 7, 2007
세계�보,The colorectal cancer drug Eloxatin, which was approved in America in August 2002, only made it to Japan when desperate patients-turned-activists staged

Japan's cancer refugees  -  Feb 22, 2007
Washington Times,The colorectal cancer drug Eloxatin, which was approved in America in August 2002, only made it to Japan when desperate patients-turned-activists staged

Sanofi Fourth-Quarter Profit Falls 4.2% on Plavix (Update5)  -  Feb 13, 2007
BloombergThe company is working on drugs to treat depression and Alzheimer's disease as well as studies to expand the use of Eloxatin and Taxotere,

Worries Remain for Sanofi-Aventis  -  Feb 13, 2007
TheStreet.com...the April patent expiration for the insomnia drug Ambien in the US and generic versions of the colorectal cancer drug Eloxatin in Europe.

RPT Sanofi-Aventis FY results top consensus; 18 treatments in ...  -  Feb 13, 2007
Forbes,The company said it expects the same rate of increase in 2007 despite the end of patent protection for Ambien in the US and generic competition to Eloxatin

Sanofi-Aventis 4Q profits fall on generic competition  -  Feb 13, 2007
newratings.comSanofi Aventis has already lost the market exclusivity for selling its cancer drug, Eloxatin, and expected to face generic competition for Ambien,

More drugs added to colon-cancer guide  -  Jan 29, 2007
United Press International29 (UPI) -- The drug-therapy duo of Roche's Xeloda and Sanofi-aventis' Eloxatin has been added to the national colon-cancer guidelines.

Sanofi-aventis 2006: In a Difficult Environment, Another Year of ...  -  Feb 12, 2007
MSN MoneyThe FDA has granted a pediatric extension for Eloxatin(R) in the United States, extending the data protection period by six months until February 2007,

Idera Pharmaceuticals Appoints Dr. Alice Bexon, Vice President of ...  -  Feb 21, 2007
Business Wire (press release),Prior to her six years at Roche, Dr. Bexon was Medical Director for Eloxatin ® and Ametycine ® for Sanofi-Synthelabo, now sanofi-aventis.

Sanofi's New Drugs Fail to Restore Confidence as Profit Drops  -  Feb 16, 2007
Bloomberg...prescribed insomnia treatment in the US The medicine loses patent protection in April, as does the Plavix clot drug, eloxatin for cancer, and Lovenox.

Sanofi`s shaky future  -  Feb 14, 2007
Monsters and Critics.com,Sanofi said the decline in its fourth-quarter earnings per share was due to generic competition against several of its drugs, including Plavix and Eloxatin.

Access Pharmaceuticals Appoints Esteban Cvitkovic, MD as Director ...  -  Feb 13, 2007
Drug Newswire (press release),...differential efficacy profile and/or a better therapeutic index than those that are currently available is the current reality since Eloxatin's success.

Access Pharmaceuticals Appoints Esteban Cvitkovic, MD as Director ...  -  Feb 8, 2007
Earthtimes.org...adifferential efficacy profile and/or a better therapeutic index than thosethat are currently available is the current reality since Eloxatin's success.

Celebrex® Does Not Increase Effectiveness of FOLFOX  -  Feb 5, 2007
Cancer Consultants (press release),FOLFOX includes the chemotherapy agents Eloxatin® (oxaliplatin), 5-flourouracil, and leucovorin, while FOLFIRI includes Camptosar® (irinotecan),

NCCN Updates Colon Cancer Guidelines  -  Jan 29, 2007
PharmaLive.com (press release),The combination regimen CapeOX, which is capecitabine (Xeloda, Roche) and oxaliplatin (Eloxatin, sanofi-aventis), was added as an alternate option to the

NCCN Updates Colon Cancer Guidelines  -  Jan 29, 2007
Business Wire (press release),The combination regimen CapeOX, which is capecitabine (Xeloda, Roche) and oxaliplatin (Eloxatin, sanofi~aventis), was added as an alternate option to the

Appeal against Mayne Pharma dropped  -  Jan 8, 2007
The Australian,The case related to patents ending for Sanofi Aventis's anti-cancer drug, oxaliplatin, under the brand name Eloxatin, and Mayne Pharma launching its version

The Navicor Group Welcomes New Hire  -  Jan 11, 2007
PharmaLive.com (press release),As a freelancer she worked on several oncology accounts such as Tarceva, Avastin, Eloxatin, Erbitux, Herceptin and Gemzar. Brown was also a copywriter at

Cetuximab (Erbitux®) Combinations Evaluated in Rectal and ...  -  Jan 2, 2007
Cancer Consultants (press release),Researchers from Germany presented data on a phase I/II study of cetuximab, Xeloda® (capecitabine) and Eloxatin® (oxaliplatin) and concomitant radiotherapy

Erbitux® Combinations Evaluated in Rectal and Esophageal Cancer  -  Jan 2, 2007
Cancer Consultants (press release),Researchers from Germany presented results at ASTRO from a Phase I/II study of Erbitux, Xeloda® (capecitabine), Eloxatin® (oxaliplatin), and concomitant,

Sales of Eloxatin for colorectal cancer are expected to slow in ...  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as

Analysis: Ketek least of Sanofi's problems  -  Dec 18, 2006
Science Daily (press release)Several of Sanofi's drugs are facing patent expiration or challenges, including Eloxatin, Lovenox and Plavix and the FDA has delayed the approval of

Cancer drug Erbitux shows mixed results in tests  Nov 6, 2006
...used alone prolonged the lives of colon cancer patients who failed treatment with a group of drugs that included Pfizer's Camptosar and Sanofi-Aventis' Eloxatin ... -Columbus Dispatch, Bleak outlook for Sanofi-aventis  Oct 31, 2006
Specifically, Eloxatin is facing patent expiration. ... Taxotere sales were up 5.1 percent to $547 million, and Eloxatin sales rose 1.7 percent to $523 million. ... -Monsters and Critics.com, Sanofi-aventis Announces Third Quarter Sales and Earnings for 2006 ...  Oct 31, 2006
1,821 +13.2% Plavix(R) 543 +2.5% 1,688 +11.2% Stilnox(R)/Ambien(R)/ Ambien CR(TM) 538 +33.8% 1,446 +29.9% Taxotere(R) 429 +5.1% 1,315 +9.0% Eloxatin(R) 417 +1.7 ... -PR Newswire (press release), Piribo: New Report on Prospects for Injectable Generic Drugs  Oct 26, 2006
...in 2010? - In which countries does Pliva market its generic version of Sanofi-Aventis' Eloxatin (oxaliplatin)? - Which companies ... -Emediawire (press release), Pipeline/Commercial Insight: Colorectal Cancer - Shaping the ...  Oct 12, 2006
Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components ... -Pharmaceutical Business Review Avastin® Improves PFS Following XELOX or FOLFOX for Colorectal ...  Oct 13, 2006
FOLFOX-4 (infused 5-fluorouracil/leucovorin plus Eloxatin® (oxaliplatin) is the current standard therapy for patients with advanced colorectal cancer. ... -Cancer Consultants (press release), XELOX as Effective as FOLFOX in Advanced Colorectal Cancer  Oct 11, 2006
...colorectal cancer. FOLFOX is a commonly used chemotherapy regimen consisting of 5-fluorouracil, Eloxatin®, and leucovorin. Xeloda ... -Cancer Consultants (press release), Analysis: Sanofi's Cancer Drug Promising  Oct 13, 2006
However, Sanofi could consider combining S-1 with its colorectal cancer drug Eloxatin, which could boost sales of both medications, he said. ... -International News Service, Sanofi-Aventis reports 12 percent drop in third-quarter profit  Oct 31, 2006
Sanofi-Aventis' other major products, such as cancer drugs Taxotere and Eloxatin, insomnia pill Ambien and insulin therapy Lantus also grew in the quarter. ... -International Herald Tribune, Sanofi-Aventis 3Q profit slides 12 pct  Oct 31, 2006
Sales of other blockbusters -- including cancer drugs Taxotere and Eloxatin, insomnia pill Ambien and insulin treatment Lantus -- all grew in the quarter. ... -BusinessWeek Generic Copy of a Blood Thinner Lowers Profit at Sanofi-Aventis  Oct 31, 2006
Sales of other blockbuster drugs, including the cancer drugs Taxotere and Eloxatin; an insomnia pill, Ambien; and a long-acting insulin, Lantus, all grew in ... -New York Times, Sanofi-Aventis confirms FY guidance as Q3 net falls to 1.7 bln eur ...  Oct 31, 2006
Cancer drug Taxotere posted a 5.1 pct sales increase to 429 mln, the Eloxatin colon cancer treatment saw a 1.7 pct rise in sales to 417 mln, and the diabetes ... -Hemscott, Sanofi-aventis Announces Third Quarter Sales and Earnings for 2006 ...  Oct 31, 2006
The FDA has granted a pediatric extension for Eloxatin® in the United States, extending the data protection period by six months until February 2007. ... -Yahoo! News (press release) Debiopharm honors cancer research in Lausanne  Oct 11, 2006
The company is known in particular for having several products such as Eloxatin®, treatment of choice for colorectal cancer, and Decapeptyl® and Trelstar ... -innovations report, Patients denied drugs in postcode lottery  Sep 23, 2006
Eloxatin ... Eloxatin in combination with standard chemotherapy is the most effective treatment advance in 15 years for patients with early-stage colon cancer. ... -Scotsman

Eloxatin®, 5-FU and Camptosar® Effective for Metastatic Gastric ...  Sep 18, 2006
Researchers from Korea have reported that the combination of Eloxatin (oxaliplatin), 5FU/leucovorin and Camptosar (irinotecan) is effective palliative therapy ... -Cancer Consultants

Eloxatin®, 5-FU, Leucovorin Regimen Safe and Effective for ...  Sep 19, 2006
Researchers involved in 4 randomized trials evaluating Eloxatin, 5-FU, leucovorin (FOLFOX4) for adjuvant, first line or second line therapy of colorectal ... -Cancer Consultants

FOLFOX4 Safe and Effective in Selected Elderly Colorectal Cancer ...  Sep 19, 2006
According to the combined results of four clinical trials, use of the FOLFOX4 chemotherapy regimen (Eloxatin® plus 5-fluorouracil/leucovorin, administered ... -Cancer Consultants

Poniard Pharmaceuticals Shareholders Approve One-for-Six Reverse ...  Sep 22, 2006
If found to be safe and effective, picoplatin could be a neuropathy-sparing substitute for oxaliplatin (Eloxatin(R)), which is part of the FOLFOX regimen that ... -PR Newswire

Ovarian cancer: platinum-based therapy still the gold standard  Sep 11, 2006
Given the proven efficacy of cisplatin and paclitaxel, there may be potential for other platinum drugs such as Sanofi-Aventis's Eloxatin (oxaliplatin) for ... -Pharmaceutical Business Review

VITAL SIGNS - The pharmaceuticals and biotechnology synopsis  Sep 18, 2006
Oxaliplatin, sold under the brand name Eloxatin, is a core anti-cancer product used in the treatment of stage III and metastatic colorectal cancer. ... -egoli.com.au

Passion for cycling spurs cancer drive  Sep 16, 2006
10, the PharmaFliers, sponsored internally by Eloxatin, took to the streets of Philadelphia along with 1,400 cyclists from across the eastern seaboard. ... -Dailyrecord.com

Cougar Biotechnology Appoints Dr. Russell Ellison to Board of ...  Sep 11, 2006
Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo, where he was responsible for several key oncology products including Eloxatin (oxaliplatin) for ... -Genetic Engineering News

Addition of Camptosar® to Gemzar® Does Not Improve Survival with ...  Sep 8, 2006
However, there is evolving evidence that the addition of a platinum compound to Gemzar, Eloxatin® (oxaliplatin), Elleance® (epirubicin) or Tarceva (erlotanib ... -Cancer Consultants

Sales of Eloxatin for colorectal cancer are expected to slow in ...  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),Sales of Eloxatin for colorectal cancer are expected to slow in the coming years as generic oxaliplatin begins to enter the EU markets, according to a new ...

PRODUCT MARKETING NEWS  -  Nov 15, 2006
PharmaLive.com (press release),Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components ...

UPDATE: Sanofi-Aventis 3Q Hit By Plavix Loss  -  Nov 21, 2006
Easy Bourse (Communiqués de presse),Sanofi-Aventis' other major products, such as cancer drugs Taxotere and Eloxatin, insomnia pill Ambien and insulin therapy Lantus also grew in the quarter. ...

Colorectal Cancer - Every Day Counts  -  Nov 21, 2006
CNW Telbec (Communiqués de presse),Ontario patients should not be denied funding for oxaliplatin (Eloxatin) on the basis that the medication has not received approval for marketing from Health ...



Colorectal cancer Prevent it or treat it  11 Apr 2006
...do so. Ontario and Alberta are also not even paying for one of the most standard of treatments, Oxaliplatin (Eloxatin). Patients ... - Canada NewsWire

Tomudex® Plus Eloxatin® Effective in Gemzar®-Resistant ...  Mar 24, 2006
...metastatic pancreatic cancer who have failed Gemzar (gemcitabine) based regimens benefit from treatment with Tomudex (raltitrexed) and Eloxatin (oxaliplatin). ... - Cancer Consultants

Tomudex® Plus Eloxatin® Effective in Gemzar®-Resistant ...  Mar 23, 2006
...to an article recently published in the British Journal of Cancer, treatment consisting of Tomudex® (raltitrexed) and Eloxatin® (oxaliplatin) provides ... - Cancer Consultants

Pt used in pancreatic cancer treatment - 27th March 2006  Mar 27, 2006
Researchers found that the use of Tomudex (raltitrexed) and Eloxatin (oxaliplatin) yielded results in half of those patients who had failed to respond to ... - Platinum today

Erbitux® Plus Camptosar® Effective in Patients with Colorectal ...  Mar 29, 2006
Patients were considered to be heavily pre-treated and had cancer that had progressed following prior therapies, including Eloxatin® (oxaliplatin) and ... - Cancer Consultants

Health council urges NIS 466m. expansion of services  Mar 29, 2006
...slow-release insulins such as Lantus, Levemir, Humalog, Apidra and Novorapid (for diabetics, eliminating previous restrictions); Eloxatin for stage III ... - Jerusalem Post

Debiopharm SA Invests in Nanocarrier Mezzanine Funding Round  Mar 30, 2006
Debiopharm has developed and registered three products with combined sales in excess of $2.2bn in 2005: Eloxatin®, one of sanofi-aventis' leading marketed ... - Yahoo! News

Genta Incorporated Announces Fourth Quarter and Year End 2005 ...  Mar 10, 2006
Most recently, Mr. Sanders was Vice-President, Oncology Sales, at sanofi-aventis, where he led the Eloxatin(R), Taxotere(R), and ELITEK(R) sales teams. ... - PR Newswire

Debiopharm SA Presented Results of a Double-Blind Placebo ...  09 Feb 2006
Debiopharm has developed and registered three products with combined sales in excess of $2.2bn in 2005: Eloxatin®, one of sanofi-aventis' leading marketed ... - Yahoo! News

Doxil®/Eloxatin® May Provide a Treatment Option in Advanced ...  Feb 6, 2006
...published in Gynecologic Oncology, the chemotherapy combination consisting of Doxil® (pegylated liposomal doxorubicin) plus Eloxatin® (oxaliplatin) may ... - Cancer Consultants

Xaliproden May Reduce Side Effect Caused by Eloxatin® in ...  Feb 6, 2006
...trials, appears to reduce the risk of peripheral neuropathy, a common side effect associated with the use of the chemotherapy agent Eloxatin® (oxaliplatin) in ... - Cancer Consultants

Sanofi-Aventis 4Q Pharma Result In-Line -SG  Jan 30, 2006
However, the market might be concerned by the rest of Pharma's decline and, in the US, persistent weak growth of Taxotere and slowdown of Eloxatin." Stock -0.9 ... - New Ratings

Sanofi-aventis Posts Dynamic Growth in 2005 Full-Year Consolidated ...  Jan 30, 2006
2005 as a whole, sales growth in Europe was boosted by a dynamic performance across the entire portfolio, especially Lantus® (up 40.5%), Eloxatin® (up 31.4 ... - Yahoo! News

Genta Appoints Seasoned Pharma Executive, Lloyd Sanders, as Vice ...  Jan 17, 2006
Most recently, Mr. Sanders was Vice President, Oncology Sales, at Sanofi-Aventis, where he led the Eloxatin(R), Taxotere(R), and ELITEK(R) sales teams. ... - PharmaLive.com

Millennium Announces Appointments of Executive Vice President of ...  Jan 25, 2006
...to the Company from sanofi-aventis, where he led the US oncology business unit, a $2 billion business with blockbuster brands such as Eloxatin® and Taxotere ... - Yahoo! News

Sanofi Q4 sales up 7 pct, raises 2005 EPS forecast  Jan 29, 2006
Growth was driven by Plavix and Lovenox, though sales came in below expectations, cancer treatments Eloxatin and Taxotere and Sanofi's vaccines business, which ... - MSN Money

Drugmakers' 4Q Profit, Revenue Rises  Jan 30, 2006
...and 18.3 percent sales rise. Other growth drivers included cancer treatments Eloxatin and Taxotere. Sanofi-Aventis said it expects ... - Houston Chronicle

Sanofi raises growth goal, obesity pill on track  Jan 30, 2006
...sales growth was driven by bloodthinners Plavix and Lovenox -- though their sales came in below the Reuters consensus -- cancer drugs Eloxatin and Taxotere and ... - Reuters

Sanofi 4Q overshadowed by impending legislation  Feb 1, 2006
Sales increased by 47.5 per cent to $1.47 billion. Eloxatin, for colorectal cancer, gained a 31 per cent increase in sales to $1.89 billion. ... - In-PharmaTechnologist.com

Drugmakers‘ 4Q Profit, Revenue Rises  Jan 30, 2006
...percent and 18.3 percent sales rise. Other growth drivers included cancer treatments Eloxatin and Taxotere. Last week, the US Food ... - Leading The Charge

ASCO-GI: Serotonin Receptor Agonist Blocks Neuropathy in Colon ...  Jan 30, 2006
...a phase III trial presented at the ASCO/ASTRO Gastrointestinal Cancer symposium, the 325 patients who were randomized to six months of Eloxatin (oxaliplatin), 5 ... - MedPage Today

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional